The fourth quarter marked a continuation of weak earnings for many major South Korean pharma firms, hurt by factors including the continued impact of a long-running doctors’ protest against medical reforms at home, as well as a strong US dollar amid political uncertainties in Korea.
Korea Q4 Roundup: Overseas Sales, M&A Provide Growth Amid General Weakness
Hanmi Dispute Finally Ends
Several major South Korean pharma firms benefited from solid sales of new drugs, and in some cases M&A deals, outside the country, although overall growth was generally weak. Meanwhile, a long-running leadership dispute at Hanmi has been resolved.
More from South Korea
More from Business
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
• By
Merck & Co., which already has an oral PCSK9 inhibitor in Phase III, licensed Hengrui’s Lipoprotein(a)-lowering small molecule HRS-5346 outside of Greater China for $200m up front.